Introduction
The N-terminal domains of MdmX or Mdm2 are highly homologous and have similar conformation (Figure 1a & b) . There are three binding pockets for a p53 binding peptide (p53p), defined as F19, W23 and L26 on their surfaces. Current Mdm2 inhibitors including nutlin-3a exhibit weak binding affinity to MdmX. Nutlin-3a (Figure 1c ) mimics p53p with high binding affinity to Mdm2 (Kd ~ 20 nM) but very weak to MdmX (Kd ~ 29 M). The L26 pocket significantly differentiates the binding affinities of nutlin-3a between Mdm2 and MdmX, but detailed mechanism remains unclear. 
Results and Discussion

Drug
. (a). A protein target model is formed by a N-terminal domain in complex with a short p53p peptide. (b) A small molecule compound mimicking p53p
short is used as a positive control. by screening virtual fragment library. Potent Mdm2-specific, MdmX-specific and dual specific inhibitors will be generated through fusing target-specific functional group to the scaffold. New inhibitors will be evaluated for their anticancer activities with cancer cell models. 
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